Postdoc Fellowship for KM Lamar in support of: Defining the molecular mechanisms of CHD2 in Lennox-Gastaut Syndrome

Project: Research project

Project Details


Lennox-Gastaut syndrome (LGS) is an early-onset epileptic encephalopathy with
seizures that are often refractory to treatment. In recent years, next generation
sequencing has revealed several novel genes associated with LGS, however little is
known about how pathogenic variation in these genes leads to disease. Improved
treatment options are necessary to improve the outcome and quality of life of LGS
patients and the first step in finding drug targets will be to better understand the
molecular biology of these disrupted genes. Pathogenic variants in the CHD2 gene are
associated with epileptic encephalopathy, including several LGS cases. CHD2 is a
chromatin remodeling protein associated with sites of active transcription. Our
hypothesis is that disruption of CHD2 will lead to decreased and/or aberrant binding of
CHD2 to its genomic targets, resulting in misregulation of gene expression. In order to
study the function and molecular mechanisms of CHD2 we have disrupted one copy of
CHD2 in induced pluripotent stem cells (iPSCs) using the CRISPR/Cas9 system. We
differentiated CHD2 heterozygous cell lines (CHD2+/-) into neuronal progenitor cells
(NPCs) and cortical excitatory neurons to study the effect of CHD2 disruption in human
cell models. To identify genes misregulated upon CHD2 disruption, we will perform
mRNA sequencing in CHD2+/- NPCs and wildtype (WT) controls at different points in
differentiation from iPSCs to NPCs. To determine genome-wide CHD2 occupancy, we
will perform chromatin immunoprecipitation followed by next generation sequencing
(ChIP-Seq) in WT NPCs. We will then correlate the results of CHD2 occupancy with the
data on which genes are misregulated upon CHD2 disruption to identify a set of
candidate genes that are regulated by CHD2. Secondly, we plan to identify binding
partners of CHD2 in NPCs and cortical neurons by performing co-immunoprecipitation
of CHD2 followed by mass spectrometry. Our hypothesis is that CHD2 will bind master
regulators of neurodevelopment, along with novel proteins, which will illuminate new
and possibly unexpected pathways in which CHD2 is involved. Combined, the
identification of CHD2 genomic targets, regulated genes, and binding partners in human
neuronal cell types will improve our understanding of the biological mechanisms behind
CHD2-associated epilepsies and point toward novel drug targets for LGS.
Effective start/end date9/1/188/31/20


  • LGS Foundation (Agmt 11/8/18)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.